Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Benefit of Repeated Injections of IncobotulinumtoxinA for Pain Reduction in Adults with Cervical Dystonia and Moderate or Severe Baseline Pain: An Analysis of Pooled Data
Movement Disorders
P8 - Poster Session 8 (5:30 PM-6:30 PM)
3-004
Pain is a common and disabling symptom of CD.
This pooled analysis assessed pain reduction during repeated incobotulinumtoxinA (incoA) injections in adults with moderate or severe cervical dystonia (CD)-related pain at baseline.
Pooled pain data from four phase 3 and 4 studies in adults with moderate/severe CD-related pain at baseline were analyzed over five injection cycles (IC1?IC5). One study was placebo-controlled, such that patients who received placebo in IC1 received incoA in IC2?IC5 (placebo/incoA group). All other patients received incoA at every IC (incoA group). Pain was assessed at each injection visit (IV) and control visit (CV) 4 weeks post-injection using the TWSTRS-pain severity scale or a pain VAS; score range 0?10 for both scales and pain scores of 3.5?10 categorized as moderate/severe. Response was defined as ≥30% or ≥50% reduction in baseline pain score, reflecting clinically relevant improvements.
Of 451 patients with moderate/severe baseline pain, 396 (87.8%) received incoA and 55 (12.2%) placebo in IC1. Of these incoA- and placebo-treated patients, 47.7% and 12.7% achieved ≥30% pain reduction at CV1 (p<0.0001 Wald-test for difference); the corresponding data for ≥50% pain reduction were 28.8% and 7.3% (p<0.0001 Wald-test for difference). During IC2?IC5, where all patients received incoA, pain response rates at CVs in either group ranged from 41.2?58.3% for ≥30% pain reduction and from 25.0?36.8% for ≥50% pain reduction.
Patients with moderate/severe CD-related pain at baseline experienced clinically relevant and sustained improvements in pain over repeated incoA injection cycles.
Authors/Disclosures
Alberto Albanese, MD (Universita Cattolica Sacro Cuore)
PRESENTER
Dr. Albanese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ipsen pharma. Dr. Albanese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merz pharms. Dr. Albanese has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers Publishing Group. Dr. Albanese has a non-compensated relationship as a President with International Association on Parkinsonism and Related Disorders that is relevant to AAN interests or activities.
No disclosure on file
No disclosure on file
No disclosure on file
Michael Althaus (Merz Pharmaceuticals GmbH) Michael Althaus has received personal compensation for serving as an employee of Merz Pharmaceuticals.
No disclosure on file
No disclosure on file
No disclosure on file
H. A. Jinnah, MD, PhD, FAAN (Emory University) Dr. Jinnah has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takaha/Ene. Dr. Jinnah has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ipsen. Dr. Jinnah has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ipsen. Dr. Jinnah has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. The institution of Dr. Jinnah has received research support from Addex. The institution of Dr. Jinnah has received research support from Aeon. The institution of Dr. Jinnah has received research support from Revance. The institution of Dr. Jinnah has received research support from Jazz.